Literature DB >> 27515775

Sarcopenia from mechanism to diagnosis and treatment in liver disease.

Srinivasan Dasarathy1, Manuela Merli2.   

Abstract

Sarcopenia or loss of skeletal muscle mass is the major component of malnutrition and is a frequent complication in cirrhosis that adversely affects clinical outcomes. These include survival, quality of life, development of other complications and post liver transplantation survival. Radiological image analysis is currently utilized to diagnose sarcopenia in cirrhosis. Nutrient supplementation and physical activity are used to counter sarcopenia but have not been consistently effective because the underlying molecular and metabolic abnormalities persist or are not influenced by these treatments. Even though alterations in food intake, hypermetabolism, alterations in amino acid profiles, endotoxemia, accelerated starvation and decreased mobility may all contribute to sarcopenia in cirrhosis, hyperammonemia has recently gained attention as a possible mediator of the liver-muscle axis. Increased muscle ammonia causes: cataplerosis of α-ketoglutarate, increased transport of leucine in exchange for glutamine, impaired signaling by leucine, increased expression of myostatin (a transforming growth factor beta superfamily member) and an increased phosphorylation of eukaryotic initiation factor 2α. In addition, mitochondrial dysfunction, increased reactive oxygen species that decrease protein synthesis and increased autophagy mediated proteolysis, also play a role. These molecular and metabolic alterations may contribute to the anabolic resistance and inadequate response to nutrient supplementation in cirrhosis. Central and skeletal muscle fatigue contributes to impaired exercise capacity and responses. Use of proteins with low ammoniagenic potential, leucine enriched amino acid supplementation, long-term ammonia lowering strategies and a combination of resistance and endurance exercise to increase muscle mass and function may target the molecular abnormalities in the muscle. Strategies targeting endotoxemia and the gut microbiome need further evaluation.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical outcomes; Hyperammonemia; Leucine; Myostatin; Sarcopenia; mTORC1

Mesh:

Substances:

Year:  2016        PMID: 27515775      PMCID: PMC5116259          DOI: 10.1016/j.jhep.2016.07.040

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  141 in total

1.  The dose-dependent effects of endotoxin on protein metabolism in two types of rat skeletal muscle.

Authors:  Miroslav Kovarik; Tomas Muthny; Ludek Sispera; Milan Holecek
Journal:  J Physiol Biochem       Date:  2012-02-07       Impact factor: 4.158

2.  Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value.

Authors:  Puneeta Tandon; Michael Ney; Ivana Irwin; Mang M Ma; Leah Gramlich; Vincent G Bain; Nina Esfandiari; Vickie Baracos; Aldo J Montano-Loza; Robert P Myers
Journal:  Liver Transpl       Date:  2012-10       Impact factor: 5.799

3.  Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis.

Authors:  Jia Qiu; Cynthia Tsien; Samjhana Thapalaya; Arvind Narayanan; Conrad Chris Weihl; James K Ching; Bijan Eghtesad; Kamini Singh; Xiaoming Fu; George Dubyak; Christine McDonald; Alex Almasan; Stanley L Hazen; Sathyamangla V Naga Prasad; Srinivasan Dasarathy
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-08-14       Impact factor: 4.310

4.  Hypothalamic-pituitary-gonadal function in men with cirrhosis of the liver.

Authors:  N A Mowat; C R Edwards; R Fisher; A S McNeilly; J R Green; A M Dawson
Journal:  Gut       Date:  1976-05       Impact factor: 23.059

5.  Muscle wasting is associated with mortality in patients with cirrhosis.

Authors:  Aldo J Montano-Loza; Judith Meza-Junco; Carla M M Prado; Jessica R Lieffers; Vickie E Baracos; Vincent G Bain; Michael B Sawyer
Journal:  Clin Gastroenterol Hepatol       Date:  2011-09-03       Impact factor: 11.382

6.  Splanchnic and leg exchange of free fatty acids in patients with liver cirrhosis.

Authors:  M Merli; L S Eriksson; L Hagenfeldt; J Wahren
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

7.  Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis.

Authors:  S Hirsch; D Bunout; P de la Maza; H Iturriaga; M Petermann; G Icazar; V Gattas; G Ugarte
Journal:  JPEN J Parenter Enteral Nutr       Date:  1993 Mar-Apr       Impact factor: 4.016

8.  Neurotoxicity of ammonia and fatty acids: differential inhibition of mitochondrial dehydrogenases by ammonia and fatty acyl coenzyme A derivatives.

Authors:  J C Lai; A J Cooper
Journal:  Neurochem Res       Date:  1991-07       Impact factor: 3.996

9.  Perioperative immunonutrition in patients undergoing liver transplantation: a randomized double-blind trial.

Authors:  Lindsay D Plank; Sachin Mathur; Edward J Gane; Sze-Lin Peng; Lyn K Gillanders; Kerry McIlroy; Carolina Paras Chavez; Philip C Calder; John L McCall
Journal:  Hepatology       Date:  2015-01-05       Impact factor: 17.425

10.  Myostatin is a skeletal muscle target of growth hormone anabolic action.

Authors:  Wei Liu; Scott G Thomas; Sylvia L Asa; Nestor Gonzalez-Cadavid; Shalendar Bhasin; Shereen Ezzat
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

View more
  131 in total

1.  Report from the American Society of Transplantation on frailty in solid organ transplantation.

Authors:  Jon Kobashigawa; Darshana Dadhania; Sangeeta Bhorade; Deborah Adey; Joseph Berger; Geetha Bhat; Marie Budev; Andres Duarte-Rojo; Michael Dunn; Shelley Hall; Meera N Harhay; Kirsten L Johansen; Susan Joseph; Cassie C Kennedy; Evan Kransdorf; Krista L Lentine; Raymond J Lynch; Mara McAdams-DeMarco; Shunji Nagai; Michael Olymbios; Jignesh Patel; Sean Pinney; Joanna Schaenman; Dorry L Segev; Palak Shah; Lianne G Singer; Jonathan P Singer; Christopher Sonnenday; Puneeta Tandon; Elliot Tapper; Stefan G Tullius; Michael Wilson; Martin Zamora; Jennifer C Lai
Journal:  Am J Transplant       Date:  2018-12-22       Impact factor: 8.086

2.  A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.

Authors:  Elizabeth J Carey; Jennifer C Lai; Christopher Sonnenday; Elliot B Tapper; Puneeta Tandon; Andres Duarte-Rojo; Michael A Dunn; Cynthia Tsien; Eric R Kallwitz; Vicky Ng; Srinivasan Dasarathy; Matthew Kappus; Mustafa R Bashir; Aldo J Montano-Loza
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

3.  Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.

Authors:  Rahima A Bhanji; Carlos Moctezuma-Velazquez; Andres Duarte-Rojo; Maryam Ebadi; Sunita Ghosh; Christopher Rose; Aldo J Montano-Loza
Journal:  Hepatol Int       Date:  2018-06-07       Impact factor: 6.047

Review 4.  Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.

Authors:  Jaividhya Dasarathy; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Alcohol Clin Exp Res       Date:  2017-07-11       Impact factor: 3.455

5.  Skeletal muscle loss phenotype in cirrhosis: A nationwide analysis of hospitalized patients.

Authors:  Adil Vural; Amy Attaway; Nicole Welch; Joe Zein; Srinivasan Dasarathy
Journal:  Clin Nutr       Date:  2020-04-03       Impact factor: 7.324

6.  Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.

Authors:  Maiko Namba; Akira Hiramatsu; Hiroshi Aikata; Kenichiro Kodama; Shinsuke Uchikawa; Kazuki Ohya; Kei Morio; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Tomokazu Kawaoka; Masataka Tsuge; Michio Imamura; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2019-09-04       Impact factor: 7.527

7.  Is sarcopenia a prognostic factor after living donor liver transplantation?

Authors:  Akira Umemura; Takeshi Takahara; Hiroyuki Nitta; Yasushi Hasegawa; Akira Sasaki
Journal:  Hepatobiliary Surg Nutr       Date:  2017-08       Impact factor: 7.293

8.  Exercise and physical activity in cirrhosis: opportunities or perils.

Authors:  Annette Bellar; Nicole Welch; Srinivasan Dasarathy
Journal:  J Appl Physiol (1985)       Date:  2020-04-02

Review 9.  Sarcopenia in cirrhosis: A practical overview.

Authors:  Amritpal Dhaliwal; Matthew J Armstrong
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

Review 10.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.